{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:08:55Z","timestamp":1792645735787,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jhep.2013.02.022","type":"journal-article","created":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T16:05:58Z","timestamp":1362413158000},"page":"81-88","source":"Crossref","is-referenced-by-count":841,"title":["A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C"],"prefix":"10.1016","volume":"59","author":[{"given":"Bruno","family":"Sangro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gomez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"de la Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"I\u00f1arrairaegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ignacio","family":"Riezu-Boj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Sarobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lasarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"P\u00e9rez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.02.022_b0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.02.022_b0010","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.02.022_b0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1053\/j.gastro.2011.03.006","article-title":"Targeted therapies for hepatocellular carcinoma","volume":"140","author":"Villanueva","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.02.022_b0020","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10620-008-0447-z","article-title":"Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature","volume":"54","author":"Oqui\u00f1ena","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2013.02.022_b0025","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/hep.22626","article-title":"A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma","volume":"49","author":"Palmer","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.02.022_b0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.02.022_b0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhep.2013.02.022_b0040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri2253","article-title":"The reverse stop-signal model for CTLA4 function","volume":"8","author":"Rudd","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2013.02.022_b0045","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1126\/science.272.5265.1170","article-title":"Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4","volume":"272","author":"Mareng\u00e8re","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jhep.2013.02.022_b0050","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","article-title":"Molecular basis of T cell inactivation by CTLA-4","volume":"282","author":"Lee","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhep.2013.02.022_b0055","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2013.02.022_b0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2013.02.022_b0065","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2013.02.022_b0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.02.022_b0075","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.02.022_b0080","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.02.022_b0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2013.02.022_b0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","article-title":"Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver","volume":"35","author":"Bruix","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.02.022_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2013.02.022_b0100","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2013.02.022_b0105","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2007-11-125435","article-title":"CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion","volume":"112","author":"Kavanagh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2013.02.022_b0110","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2013.02.022_b0115","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.25639","article-title":"Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma","volume":"117","author":"Rini","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2013.02.022_b0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2011.37.5394","article-title":"Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma","volume":"30","author":"Tarhini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.02.022_b0125","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2013.02.022_b0130","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-10-2011","article-title":"Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Park","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2013.02.022_b0135","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1128\/JVI.02248-06","article-title":"Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection","volume":"81","author":"Larrea","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2013.02.022_b0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jhep.2010.07.014","article-title":"Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection","volume":"54","author":"Riezu-Boj","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.02.022_b0145","doi-asserted-by":"crossref","first-page":"e1000313","DOI":"10.1371\/journal.ppat.1000313","article-title":"Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1\/CTLA-4 blockade","volume":"5","author":"Nakamoto","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2013.02.022_b0175","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","article-title":"Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization","volume":"134","author":"Nakamoto","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.02.022_b0180","article-title":"Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma","author":"Cabrera","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jhep.2013.02.022_b0160","doi-asserted-by":"crossref","first-page":"607851","DOI":"10.1155\/2012\/607851","article-title":"Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma","volume":"2012","author":"Nagai","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jhep.2013.02.022_b0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.seminoncol.2010.09.001","article-title":"Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy","volume":"37","author":"Callahan","year":"2010","journal-title":"Semin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781300144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781300144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T04:52:29Z","timestamp":1539838349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781300144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S016882781300144X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.02.022","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}